Donanemab phase 3 TRAILBLAZER-ALZ 2: amyloid clearance slows Alzheimer's decline — integrated Alzheimer's Disease Rating
Summary
The full phase 3 results of donanemab (Kisunla, Eli Lilly) in early symptomatic Alzheimer's disease published in JAMA showed that complete amyloid clearance — achieved in 40% of participants — was associated with the greatest slowing of clinical decline. Patients who achieved plaque clearance and stopped treatment maintained benefit, suggesting disease modification persists after drug discontinuation. TRAILBLAZER-ALZ 2 enrolled 1,736 participants across 277 sites in 8 countries.
Why it matters
Donanemab's finding that patients who achieve plaque clearance and stop treatment maintain benefit is the strongest evidence yet for genuine Alzheimer's disease modification — not just symptomatic improvement. If amyloid clearance followed by treatment discontinuation produces durable benefit, it transforms the therapeutic model from chronic maintenance therapy to potentially curative treatment course.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial